Who are the major stakeholders for SII? What strategic influence does each of them have on SII's vaccine manufacturing and supply allocation? 3. What are the advantages and risks for SII of having a centralized production facility for COVID-19 vaccines in India in terms of efficiency and responsiveness? 4. For SII, what are the advantages and risks associated with importing critical components from a single source or country? 5. What are the characteristics of demand and supply side uncertainties for SII in terms of COVID-19 vaccines? What might be a suitable supply chain configuration? 6. What strategic choices does Poonawalla have for honouring SII's supply commitment to its global partners and for meeting vaccine demand in his own country?